A.R.T. Advisors’s vTv Therapeutics VTVT Stock Holding History

A.R.T. Advisors’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-638	Closed	-$19K	–	1685
2018 Q3	$19K	Sell	638 -1,118	-64%	-$52.4K	﹤0.01%	1349
2018 Q2	$108K	Buy	+1,756	New	+$130K	﹤0.01%	1291

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

A.R.T. Advisors's VTVT Position: Q4 2018 in Review

A.R.T. Advisors sold out of vTv Therapeutics (VTVT) in Q4 2018, closing a stake of 638 shares — an estimated $19K sold.

A.R.T. Advisors first reported a position in VTVT in Q2 2018 and held it in 2 quarters. The position peaked at $108K in Q2 2018. 17 funds tracked by Wall St. Rank hold VTVT as of Q4 2018.

A.R.T. Advisors reported no remaining vTv Therapeutics position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 638 vTv Therapeutics shares in Q4 2018, an estimated $19K.
A.R.T. Advisors first reported a position in vTv Therapeutics in Q2 2018 and held it in 2 quarters.
A.R.T. Advisors's vTv Therapeutics position peaked at $108K in Q2 2018.
17 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.